Golocdacimab
Based on 2 publication(s) in Google Scholar
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.11%
- CAS No.: 2418540-63-1
- 분자량:146.64 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
OLR1
In Vivo
1. Directly bind to and block the LOX-1 receptor:
MEDI6570 specifically binds to LOX-1, antagonizes its interaction with ligands such as oxLDL, and inhibits the activation of the LOX-1 signaling pathway. Abnormal activation of the LOX-1 signaling pathway is a key contributor to increased cardiovascular risk in type 2 diabetes.
2. Regulate key inflammatory biomarkers:
It regulates inflammatory biomarkers such as IL-16 and IL-18 that are associated with the LOX-1 signaling pathway. These biomarkers represent potential nodes linking the LOX-1 signaling pathway to cardiovascular risk. By altering their expression levels, MEDI6570 interrupts the transmission of cardiovascular risk mediated by the LOX-1 signaling pathway and improves inflammation-related pathological conditions in patients with type 2 diabetes.
3. Affect neutrophil-related pathways:
It induces the production of neutrophil-related biomarkers such as CEACAM8, PRTN3, PGLYRP1, CPB1, GRN and LTBR, indicating that it can regulate neutrophil-related pathways. Neutrophils exert potential effects in LOX-1-mediated pathological responses, and this regulatory effect further interferes with the downstream pathological impacts of the LOX-1 signaling pathway.
4. Inhibit abnormal activation of multiple LOX-1-related pathways:
It regulates multiple pathological pathways associated with the LOX-1 signaling pathway, including oxidative stress, apoptosis, cell adhesion and migration, improves pathological changes caused by abnormalities of these pathways in patients with type 2 diabetes, and reduces the risk of cardiovascular complications.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
신청
ELISA, FACS, Functional assay
Product Details
-
CAS No. 2418540-63-1
-
Accession 4973
-
Synonyms MEDI6570
-
분자량 146.64 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 lambda2
-
Recommend Isotype Controls
-
Format
-
Human IgG1 lambda2
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.11%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
선적
Shipping with dry ice.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Mol Ther
Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors. [Abstract]2026 Jan 20:S1525-0016(26)00020-1. PMID: 41566775 -
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)